Companies Dominating the Doxorubicin Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson and Johnson
- Zydus Group
- Cipla Limited
- Sun Pharmaceutical Industries Ltd
- Padagis
- Reddy Laboratories Ltd.,
- Cadila Healthcare Limited
- Novartis International AG
- MicroBiopharm Japan Co. Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Ayana Pharma Ltd, in partnership with Padagis, received approval from the US FDA to launch a generic version of the drug Doxil (Doxorubicin Liposome Injection), which has been rated AB by the FDA.
- Under a definitive merger agreement between Pfizer Inc. and Seagen Inc., Pfizer Inc. plans to acquire Seagen for USD 229 per Seagen share, for a total enterprise value of USD 43 billion. Seagen develops, commercializes, and discovers transformative cancer medicines.
